Induction treatment with monoclonal antibodies for heart transplantation

Transplantation Reviews

Volumn 25, Issue 1, 2011, Pages 21-26

  Delgado, Juan F ^a   Vaqueriza, David ^a   Sánchez, Violeta ^a   Escribano, Pilar ^a   Ruiz Cano, Maria J ^a   Renes, Emilio ^a   Gómez Sánchez, Miguel A ^a   Cortina, Jose M ^a   de la Calzada, Carlos S ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; PREDNISONE; STEROID; TACROLIMUS;

ADULT; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PROTEIN INDUCTION; REVIEW; UNIVERSITY HOSPITAL;

EID: 78649652062     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2010.10.002     Document Type: Review

References (45)

1. Jiménez M.F., Díez J., Delgado J.F., et al. La insuficiencia cardiaca en el año 2005. Rev Esp Cardiol 2006, 59:55-65.
2. Gómez M., Segovia J., Alonso Pulpón L. Asistencia mecánica circulatoria y trasplante cardíaco. Indicaciones y situación en España. Insuficiencia cardiaca. Rev Esp Cardiol 2006, 6:82-94.
3. Denton M.D., Magee C.C., Sayegh M.H. Immunosuppressive strategies in transplantation. Lancet 1999, 353:1083-1091.
4. Higgins R., Kirklin J.K., Brown R.N., et al. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?. J Heart Lung Transplant 2005, 24:392-400.
5. Uber P.A., Mehra M.R. Induction therapy in heart transplantation: is there a role?. J Heart Lung Transplant 2007, 26:205-209.
6. Lindenfeld J.Á., Miller G.G., Shakar S.F., et al. Drug therapy in the heart transplant recipient: part I. Cardiac rejection and immunosuppressive drugs. Circulation 2004, 110:3734-3740.
7. Ensor C.R., Cahoon W.D., Hess M.L., et al. Induction immunosuppression for orthotopic heart transplantation: a review. Prog Transplant 2009, 19:333-341.
8. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report 2005. J Heart Lung Transplant 2005, 24:945-955.
9. Beniaminovitz A., Itescu S., Lietz K., et al. Prevention of rejection in cardiac transplantation in blockade of interleukin-2 receptor with monoclonal antibody. N Engl J Med 2000, 342:613-619.
10. Hershberger R.E., Starling R.C., Eisen H.J., et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005, 352:2705-2713.
11. Kobashigawa J., David K., Morris J., et al. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. Transplant Proc 2005, 37:1333-1339.
12. Rosenberg P.B., Vriesendorp A.E., Drazner M.H., et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart and lung transplant 2005, 24:1327-1331.
13. Mehra M.R., Zucker M.J., Wagoner L., et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 2005, 24:1297-1304.
14. Haddad M., Alghofaili F.S., Fergusson D.A., et al. Induction immunosuppression after heart transplantation: monoclonal vs. polyclonal antithymoglobulins. Is there a difference?. Interact Cardiovasc Thorac Surg 2005, 4:415-419.
15. Chatenoud L., Ferran C., Reuter A., et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 1989, 320:1420-1421. [corrected].
16. Nashan B., Moore R., Amlot P., et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997, 350:1193-1198.
17. Gibelli N.E., Pinho-Apezzato M.L., Miyatani H.T., et al. Basiliximab-chimeric anti-IL2-R monoclonal antibody in pediatric liver transplantation. Comparative study. Transplant Proc 2004, 36:956-957.
18. Liu C.L., Fan S.T., Lo C.M., et al. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination steroids and reduction of tacrolimus dosage. Liver Transpl 2004, 10:728-733.
19. Webster A.C., Playford E.G., Higgins G., et al. Interleukin 2 receptor antagonist for renal transplantation recipients: a meta-analysis of randomized trials. Transplantation 2004, 77:166-176.
20. Nashan B., Moore R., Arnlot P., et al. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 20 Intemational Study Group. Lancet 1997, 350:1193-1198.
21. Lawen J.G., Davies E.A., Mourarad G., et al. Randomised double-blind study of immunoprophilaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil containing triple therapy in renal transplantation. Transplantation 2003, 75:37-43.
22. Sheashaa H.A., Bakr M.A., Ismail A.M., et al. Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study. Am J Nephrol 2005, 25:221-225.
23. Tan J., Yang S., Wu W. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients. Transplant Proc 2005, 37:903-905.
24. Segovia J., Rodríguez-Lambert J.L., Crespo-Leiro M.G., et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 2006, 81:1542-1548.
25. Aguero J., Almenar L., Martínez Dolz L., et al. Influence of immunosuppressive regimens on short-term morbidity and mortality in heart transplantation. Clin Transplant 2008, 22:98-106.
26. Kobashigawa J.A., Miller L., Young A., et al. Does acute rejection correlate with the development of transplant coronary artery disease? A multicenter study using intravascular ultrasound. J Heart Lung Transplant 1995, 14:S221-226.
27. Møller C.H., Gustafsson F., Gluud C., et al. Interleukin-2 receptor antagonists as induction therapy after heart transplantation: systematic review with meta-analysis of randomized trials. J Heart Lung Transplant 2008, 27:835-842.
28. Flaman F., Zieroth S., Rao V., et al. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. J Heart Lung Transplant 2006, 25:1358-1362.
29. Carrier M., Leblanc M.H., Perrault L.P., et al. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. J Heart Lung Transplant 2007, 26:258-263.
30. Lorber M.I., Fastenau J., Wilson D., et al. A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation. Clin Transplant 2000, 14:479-485.
31. Keown P.A., Balshaw R., Krueger H., et al. Economic analysis of basiliximab in renal transplantation. Transplantation 2001, 71:1573-1579.
32. Hasegawa T., Imai H., Miki S. Cost evaluation of basiliximab treatment for renal transplant patients in Japan. Pharmacoeconomics 2003, 21:791-806.
33. Chilcott J.B., Holmes M.W., Walters S., et al. The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation. Transpl Int 2002, 15:486-493.
34. Polsky D., Weinfurt K.P., Kaplan B., et al. An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation. Nephrol Dial Transplant 2001, 16:1028-1033.
35. Eisen H.J., Kobashigawa J., Keogh A., et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005, 24:517-525.
36. Hosenpud J.D., Bennett L.E. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation 2001, 72:1662-1665.
37. Kobashigawa J., Miller L., Renlund D., et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate mofetil investigators. Transplantation 1998, 66:507-515.
38. Grimm M., Rinaldi M., Yonan N.A., et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-a large European trial. Am J Transplant 2006, 6:1387-1397.
39. Kobashigawa J.A., Miller L.W., Russell S.D., et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006, 6:1377-1386.
40. Kobashigawa J.A., Patel J., Furukawa H., et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006, 25:434-439.
41. Starnes V.A., Oyer P.E., Stinson E.B., et al. Prophylactic OKT3 used as induction therapy for heart transplantation. Circulation 1989, 80:III79-III83.
42. Leonard G., Messina M., Giraudi R., et al. Basiliximab in association with tacrolimus and steroids in Caucasian cadaveric renal transplanted patients: significant decrease in early acute rejection rate and hospitalization time. Clin Transplant 2004, 18:113-118.
43. Kode R., Fa K., Chowdhury S., et al. Basiliximab plus low dose cyclosporine vs OKT3 for induction immunosuppression following renal transplantation. Clin Transplant 2003, 17:369-376.
44. Chapman T.M., Keating G.M. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 2003, 63:2803-2835.
45. Boggi U., Vistoli F., Signori S., et al. Efficacy and safety of basiliximab in kidney transplantation. Expert Opin Drug Saf 2005, 4:473-490.